354 reports of this reaction
2.2% of all BLEOMYCIN SULFATE reports
#7 most reported adverse reaction
ANAEMIA is the #7 most commonly reported adverse reaction for BLEOMYCIN SULFATE, manufactured by Fresenius Kabi USA, LLC. There are 354 FDA adverse event reports linking BLEOMYCIN SULFATE to ANAEMIA. This represents approximately 2.2% of all 16,267 adverse event reports for this drug.
Patients taking BLEOMYCIN SULFATE who experience anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAEMIA is a less commonly reported adverse event for BLEOMYCIN SULFATE, but still significant enough to appear in the safety profile.
In addition to anaemia, the following adverse reactions have been reported for BLEOMYCIN SULFATE:
The following drugs have also been linked to anaemia in FDA adverse event reports:
ANAEMIA has been reported as an adverse event in 354 FDA reports for BLEOMYCIN SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAEMIA accounts for approximately 2.2% of all adverse event reports for BLEOMYCIN SULFATE, making it a notable side effect.
If you experience anaemia while taking BLEOMYCIN SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.